ストックスクリーナーアプリを入手
62.39
3.95%
2.37
アフターアワーズ：
62.39
前日終値:
$60.02
開ける：
$60.12
24時間の取引高:
2.10M
Relative Volume:
1.05
時価総額：
$7.68B
収益：
$88.04M
当期純損益:
$-784.96M
株価収益率:
-9.5492
EPS:
-6.5335
ネットキャッシュフロー:
$-534.82M
1週間 パフォーマンス:
+0.32%
1か月 パフォーマンス:
-0.80%
6か月 パフォーマンス:
+30.44%
1年 パフォーマンス:
+40.04%
1日の値動き範囲:
$60.11
$62.39
1週間の範囲:
$59.03
$63.98
52週間の値動き範囲:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
62.39 | 7.39B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Aug Catalysts: What is the long term forecast for Cytokinetics Incorporated stockShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-22 | Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:CYTK | Press Release - Stockhouse
Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP - MarketBeat
Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 By Investing.com - Investing.com Canada
Blum, Cytokinetics CEO, sells $2.2m in shares By Investing.com - Investing.com Canada
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock - MarketBeat
Fady Ibraham Malik Sells 12,033 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 - Investing.com
Cytokinetics Insiders Sold Shares Worth Over $3.6M - TradingView
Cytokinetics (CYTK) CFO share sale covers RSU tax obligations - Stock Titan
Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYT - GuruFocus
Cytokinetics (CYTK) EVP executes 8,542-share sell-to-cover for RSU taxes - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics President & CEO Sold Shares Worth Over $2.2M - TradingView
Cytokinetics (CYTK) CEO executes sell-to-cover stock sales for taxes - Stock Titan
Andrew Callos reports multiple 10b5-1 sales for CYTK (NASDAQ: CYTK) - Stock Titan
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Mizuho Boosts Cytokinetics (NASDAQ:CYTK) Price Target to $100.00 - MarketBeat
Cytokinetics Q4 2025 earnings preview - MSN
New Aficamten HCM Data On Exercise Capacity And Flexibility Might Change The Case For Investing In Cytokinetics (CYTK) - simplywall.st
Cytokinetics (CYTK) CEO receives new RSU and stock option awards - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics (CYTK) EVP awarded new stock options and RSUs - Stock Titan
Cytokinetics (CYTK) awards stock options and RSUs to chief legal officer - Stock Titan
Cytokinetics (CYTK) CFO granted RSUs and stock options - Stock Titan
[Form 4] CYTOKINETICS INC Insider Tradi... - Stock Titan
JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $75.00 - MarketBeat
CYTK Analyst Update: JP Morgan Raises Price Target to $75 | CYTK Stock News - GuruFocus
Cytokinetics stock price target raised to $75 by JPMorgan - Investing.com Canada
JPMorgan Boosts Price Target on Cytokinetics (CYTK) Amid Positiv - GuruFocus
Granahan Investment Management LLC Purchases Shares of 53,550 Cytokinetics, Incorporated $CYTK - MarketBeat
Bamco Inc. NY Makes New Investment in Cytokinetics, Incorporated $CYTK - National Today
Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation - simplywall.st
Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes - Yahoo Finance
Cytokinetics (NASDAQ:CYTK) EVP Sells $104,300.27 in Stock - MarketBeat
Stifel reiterates Cytokinetics stock rating ahead of trial data By Investing.com - Investing.com Canada
Andrew Callos 10b5-1 sales reported for CYTK (NASDAQ: CYTK) - Stock Titan
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - AOL.com
Cytokinetics (CYTK) Presents Findings on Aficamten for Cardiomyo - GuruFocus
Cytokinetics announces four presentations at the American College of Cardiology annual scientific session & expo - marketscreener.com
Cytokinetics Announces Four Presentations At The American College Of Cardiology Annual Scientific Session & Expo - TradingView
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):